NCT07197827 2025-12-24
A Study of YL242 in Subjects With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2 Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
ImmunityBio, Inc.
Merck Sharp & Dohme LLC
Dana-Farber Cancer Institute